Advertisement

Topics

Servier, Transgene Leverage Platform Tech for More Effective CAR T-Cell Therapies

06:24 EDT 29 Jun 2017 | Genetic Engineering News

Servier and Transgene have established a research collaboration to evaluate the latter’s viral vectorization technologies for use in engineering allogeneic chimeric antigen receptor (CAR) T-cell therapies, including the next generation of Servier’s early clinical-stage CAR T-cell candidate UCART19. The goal of the initially three-year collaboration is to use Transgene’s viral vector platform to develop vectorization tools that will enable faster, simpler, and more precise CAR T-cell genome modification, with fewer steps and better transgene integration yields. The ultimate aim is to use the technologies to develop more effective anticancer CAR T-cell therapies. Transgene, which is part of Institut Mérieux, could earn more than €30 million ($34.2 million), with Servier retaining rights to use the new vectors for developing its cell immunotherapy portfolio. “Allogeneic cell therapies using CAR-T open a major field of innovation in the treatment of cancer,” stated Patrick Therasse, M.D., oncology R&D director at Servier. ...

Original Article: Servier, Transgene Leverage Platform Tech for More Effective CAR T-Cell Therapies

NEXT ARTICLE

More From BioPortfolio on "Servier, Transgene Leverage Platform Tech for More Effective CAR T-Cell Therapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...